BlueCross BlueShield
Federal Employee Program

PADCEV
(enfortumab vedotin-ejfv)

Pre – PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic urothelial cancer
    a. Used as a single agent
    b. Patient has **ONE** of the following:
        i. Previous treatment with platinum-containing chemotherapy **AND ONE** of the following:
            1. programmed death receptor-1 (PD-1) inhibitor
            2. programmed death-ligand 1 (PD-L1) inhibitor
        ii. Patient is ineligible for cisplatin-containing chemotherapy and has previously received one or more prior lines of therapy

AND ALL of the following:

1. Prescriber agrees to monitor for severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
2. Prescriber agrees to monitor for new or worsening peripheral neuropathy
3. Prescriber agrees to monitor for hyperglycemia
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 2 months after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 4 months after the last dose

BlueCross BlueShield
Federal Employee Program

PADCEV
(enfortumab vedotin-ejfv)

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic urothelial cancer
    a. Used in combination with Keytruda (pembrolizumab)

AND ALL of the following:

1. Prescriber agrees to monitor for severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
2. Prescriber agrees to monitor for new or worsening peripheral neuropathy
3. Prescriber agrees to monitor for hyperglycemia
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 2 months after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 4 months after the last dose

Prior – Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic urothelial cancer
    a. Used as a single agent
    b. **NO** disease progression or unacceptable toxicity

AND ALL of the following:

BlueCross BlueShield
Federal Employee Program

PADCEV
(enfortumab vedotin-ejfv)

1. Prescriber agrees to monitor for severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
2. Prescriber agrees to monitor for new or worsening peripheral neuropathy
3. Prescriber agrees to monitor for hyperglycemia
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 2 months after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 4 months after the last dose

---

Diagnosis

Patient must have the following:

1. Locally advanced or metastatic urothelial cancer
    a. Used in combination with Keytruda (pembrolizumab)
    b. **NO** disease progression or unacceptable toxicity

AND ALL of the following:

1. Prescriber agrees to monitor for severe skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
2. Prescriber agrees to monitor for new or worsening peripheral neuropathy
3. Prescriber agrees to monitor for hyperglycemia
4. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 2 months after the last dose
5. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Padcev and for 4 months after the last dose

Prior – Approval *Renewal* Limits

Same as above